Donor Risk Index for African American Liver Transplant Recipients With Hepatitis C Virus

被引:12
|
作者
Shores, Nathan J. [1 ]
Dodge, Jennifer L. [2 ]
Feng, Sandy [2 ]
Terrault, Norah A. [2 ]
机构
[1] Tulane Univ, New Orleans, LA 70118 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
FIBROSIS PROGRESSION; RACIAL-DIFFERENCES; UNITED-STATES; SURVIVAL; OUTCOMES; GRAFT; INFECTION; IMPACT; IL28B; HCV;
D O I
10.1002/hep.26478
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
African American (AA) liver transplant (LT) recipients with hepatitis C virus (HCV) have higher rates of graft loss than other racial/ethnic groups. The Donor Risk Index (DRI) predicts graft loss but is neither race- nor disease-specific and may not be optimal for assessing donor risk for AA HCV-positive LT recipients. We developed a DRI for AA with HCV with the goal of enhancing graft loss predictions. All U.S. HCV-positive adult AA first deceased donor LTs surviving 30 days from March 2002 to December 2009 were included. A total of 1,766 AA LT recipients were followed for median 2.8 (interquartile range [IQR] 1.3-4.9) years. Independent predictors of graft loss were donor age (40-49 years: hazard ratio [HR] 1.54; 50-59 years: HR 1.80; 60+ years: HR 2.34, P<0.001), non-AA donor (HR 1.66, P<0.001), and cold ischemia time (CIT) (HR 1.03 per hour >8 hours, P=0.03). Importantly, the negative effect of increasing donor age on graft and patient survival among AAs was attenuated by receipt of an AA donor. A new donor risk model for AA (AADRI-C) consisting of donor age, race, and CIT yielded 1-year, 3-year, and 5-year predicted graft survival rates of 91%, 77%, and 68% for AADRI <1.60; 86%, 67%, and 55% for AADRI 1.60-2.44; and 78%, 53%, and 39% for AADRI >2.44. In the validation dataset, AADRI-C correctly reclassified 27% of patients (net reclassification improvement P=0.04) compared to the original DRI. Conclusion: AADRI-C identifies grafts at higher risk of failure and this information is useful for risk-benefit discussions with recipients. Use of AA donors allows consideration of older donors. (Hepatology 2013;58:1263-1269)
引用
收藏
页码:1263 / 1269
页数:7
相关论文
共 50 条
  • [31] Limiting Hepatitis C Virus Progression in Liver Transplant Recipients Using Sirolimus-Based Immunosuppression
    McKenna, G. J.
    Trotter, J. F.
    Klintmalm, E.
    Onaca, N.
    Ruiz, R.
    Jennings, L. W.
    Neri, M.
    O'Leary, J. G.
    Davis, G. L.
    Levy, M. F.
    Goldstein, R. M.
    Klintmalm, G. B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (11) : 2379 - 2387
  • [32] Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus
    Verna, Elizabeth C.
    Valadao, Rosa
    Farrand, Erica
    Pichardo, Elsa M.
    Lai, Jennifer C.
    Terrault, Norah A.
    Brown, Robert S., Jr.
    LIVER TRANSPLANTATION, 2012, 18 (04) : 461 - 467
  • [33] Harmful Effects of Viral Replication in Seropositive Hepatitis C Virus Renal Transplant Recipients
    Gentil Govantes, Miguel A.
    Esforzado, Nuria
    Cruzado, Josep M.
    Gonzalez-Roncero, Francisco M.
    Balana, Montserrat
    Saval, Nuria
    Morales, Jose M.
    TRANSPLANTATION, 2012, 94 (11) : 1131 - 1137
  • [34] The impact of donor hepatitis B virus infection on transplant outcomes in deceased donor kidney transplantation recipients
    Luo, You
    Zhang, Rui
    Hu, Xiao
    Tang, Zuofu
    Zhang, Jinhua
    Wu, Jiaqing
    Na, Ning
    Xiao, Hengjun
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2025, 44 (02) : 361 - 375
  • [35] MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis
    Gelley, Fanni
    Zadori, Gergely
    Nemes, Balazs
    Fassan, Matteo
    Lendvai, Gabor
    Sarvary, Eniko
    Doros, Attila
    Gerlei, Zsuzsanna
    Nagy, Peter
    Schaff, Zsuzsa
    Kiss, Andras
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (01) : 121 - 127
  • [36] Sofosbuvir Plus Ledispasvir for Recurrent Hepatitis C in Liver Transplant Recipients
    Kwok, Ryan M.
    Ahn, Joseph
    Schiano, Thomas D.
    Te, Helen S.
    Potosky, Darryn R.
    Tierney, Amber
    Satoskar, Rohit
    Robertazzi, Suzanne
    Rodigas, Colleen
    Sang, Michelle Lee
    Wiegel, Joshua
    Patel, Neal
    Gripshover, Janet
    Hassan, Mohamed A.
    Branch, Andrea
    Smith, Coleman I.
    LIVER TRANSPLANTATION, 2016, 22 (11) : 1536 - 1543
  • [37] Usefulness of Liver Biopsy in Anti-Hepatitis C Virus Antibody-Positive and Hepatitis C Virus RNA-Negative Kidney Transplant Recipients
    Kim, So Mi
    Kim, Hyeon Woo
    Lee, Eun-kyoung
    Park, Su Kil
    Han, Duck Jong
    Kim, Soon Bae
    TRANSPLANTATION, 2013, 96 (01) : 85 - 90
  • [38] Transplant Center Variability in Disparities for African-American Kidney Transplant Recipients
    Taber, David J.
    Gebregziabher, Mulugeta
    Srinivas, Titte
    Egede, Leonard E.
    Baliga, Prabhakar K.
    ANNALS OF TRANSPLANTATION, 2018, 23 : 119 - 128
  • [39] Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus
    Campos-Varela, Isabel
    Dodge, Jennifer L.
    Stock, Peter G.
    Terrault, Norah A.
    CLINICAL TRANSPLANTATION, 2016, 30 (09) : 1140 - 1145
  • [40] Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observational, retrospective study
    Aguilera, Victoria
    Di Maira, Tommaso
    Conde, Isabel
    Fornes-Ferrer, Victoria
    Vinaixa, Carmen
    Pallares, Carmen
    Carvalho-Gomes, Angela
    Cubells, Almudena
    Garcia, Maria
    Rubin, Angel
    Benlloch, Salvador
    Gonzalez-Dieguez, Luisa
    Miguel Molina, Jose
    Puchades, Lorena
    Xavier Lopez-Labrador, F.
    Prieto, Martin
    Berenguer, Marina
    TRANSPLANT INTERNATIONAL, 2018, 31 (06) : 649 - 657